Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT).

समान संसाधन

• Greater reductions in C-reactive protein with rosiglitazone than with glyburide or metformin despite greater weight gain
  द्वारा: Haffner, S, और अन्य
  प्रकाशित: (2007)
• Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
  द्वारा: Kahn, SE, और अन्य
  प्रकाशित: (2006)
• Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy.
  द्वारा: Lachin, J, और अन्य
  प्रकाशित: (2011)
• Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT.
  द्वारा: Kahn, SE, और अन्य
  प्रकाशित: (2011)
• Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.
  द्वारा: Zinman, B, और अन्य
  प्रकाशित: (2010)